Report: Olympus used M&A to hide losses; AngioDynamics names new execs;

> Scandal-plagued Olympus Corp.'s losses on securities investments may have once exceeded $1 billion, the Nikkei is reporting. In addition, Olympus is admitting it used M&A deals to hide losses dating back two decades. Story

> AngioDynamics has appointed Matthew Kapusta as senior VP of business development, effective Nov. 15, and Donna Haire, senior VP of regulatory, quality, clinical and medical affairs, effective immediately. AngioDynamics release

> Tim Ulatowski, former director of the Office of Compliance within CDRH, has joined as director, medical devices on the Becker Consulting expert advisory committee. Becker release

> i-Optics' EasyScan, its smart retinal imaging system, has been 510(k) cleared by the FDA. i-Optics release

> Biosensors International has announced four-year results of the LEADERS trial, showing improved long-term clinical outcomes for BioMatrix Flex, the company's Biolimus A9-eluting stent system with abluminal biodegradable polymer, versus Johnson & Johnson's ($JNJ) Cypher Select. Biosensors' release

> The Scottish Investment Bank has boosted the upper limit of its Scottish Seed Fund to £250,000. "Improving access to finance is critical if we are to emerge from the recession in a strong position," explained Gerard Kelly, head of the Scottish Investment Bank. "Recent market and evaluation evidence has demonstrated that by boosting the threshold of the Scottish Seed Fund, we have the potential to increase availability of risk capital for Scotland's seed and start up stage companies." SBI release

And Finally... A new study suggests heart patients are more likely to get expensive follow-up tests sooner than recommended if their physicians own testing equipment or get paid for interpreting results. Article